NRTI-resistance mutations & their mechanism of drug resistance M184V/I is the most prevalent mutation. M184V alone confers high-level resistance to both lamivudine and emtricitabine. A series of ...

VARIOUS ARTISTS - 'MUTATIONS' FESTIVAL, VARIOUS VENUES, BRIGHTON 5-9.11.24  The sixth edition of the ‘Mutations’ festival, ...

Scientists have identified a genetic mutation which may be the key to stopping people from craving sugary treats. The ...

In this article, we take a look at five biotech companies developing potentially transformative medicines to treat cystic ...

Patients with EGFR-mutant non-small cell lung cancer who are TKI-naïve benefited from receiving the Cyramza-Tagrisso ...

We have seen a number of dynamic changes in MDS over the last few years, and integrating them into our treatment paradigm will impact our approach, and perhaps offer a glimpse into the future." ...

In operable non-small cell lung cancer (NSCLC), molecular residual disease (MRD) detection via circulating tumor DNA (ctDNA) has emerged as a promising approach to identify individuals at high risk of ...

Operator Good morning and welcome to Ocugen's third quarter 2024 financial results and business update. [Operator ...

Q3 2024 Earnings Call Transcript November 6, 2024 Guardant Health, Inc. beats earnings expectations. Reported EPS is $-0.45, expectations were $-0.74. Operator: Hello, everyone, and welcome to the ...

Targeted therapy revolutionized cancer treatment, with gene fusions leading the way when the FDA approved imatinib in 2001 to ...